All News
RheumNow Week in Review – 2 September 2016
Dr. Jack Cush reviews highlights from this week in RheumNow:
Read Article
Nailfold Capillaroscopy Excludes Scleroderma in Raynaud’s
Nailfold capillaroscopy test had impressive 90% negative predictive value for Systemic Sclerosis (SSc)
Read Article
RheumNow Week in Review – 19 August 2016
Dr. Cush reviews the RheumNow.com highlights in rheumatology for the week ending 19 August 2016.
Read Article
RheumNow Week in Review – 12 August 2016
Watch Dr. Cush review 13 highlights from this week on RheumNow.
Read Article
faSScinate Study Shows Tocilizumab to be Effective in Systemic Sclerosis
The results of the faSScinate trial were published in Lancet showing that treatment with Actemra (tocilizumab) resulted in a reduction in skin thickness and an improvement in lung function in patients with systemic sclerosis (SSc).
Read Article
Fresolimumab (anti-TGF beta) Improves Systemic Sclerosis
Transforming growth factor (TGF-β) is known to have potent profibrotic activity and has been implicated in the pathogenesis of systemic sclerosis a futile condition with no effective disease modifying treatments.
Read Article
RheumNow Week in Review – 1 July 2016
Dr. Jack Cush reviews highlights from the news and social media in the past week on RheumNow.com
RheumNow Week in Review – 24 June 2016
Dr. Cush reviews highlights published this week at RheumNow.com.
Read Article
Netrin-1 May Promote Lung Fibrosis in Scleroderma
Mechanisms underlying the pulmonary fibrosis of systemic sclerosis are poorly understood, yet are the focus of both research and new drug development.
Read Article
Scleroderma Digital Ulcers Fail to Respond to Endothelin Antagonist
Khanna and coworkers have published the results of the DUAL-1 and DUAL-2 clinical trials (sponsored by Actelion Pharmaceuticals) testing the efficacy macitentan in reducing the number of new digital ulcers in patients with systemic sclerosis.
Read Article
faSScinate Study Shows Tocilizumab to be Effective in Systemic Sclerosis
The results of the faSScinate trial were published in Lancet showing that treatment with Actemra (tocilizumab) resulted in a reduction in skin thickness and an improvement in lung function in patients with systemic sclerosis (SSc).
Read Article
Risk Factors for Pulmonary Hypertension in Lupus
Fidler and colleagues from Toronto have recently shown that pulmonary disease is common in lupus, as they found 56% of their patients with abnormal pulmonary assessments.
Read Article
Drugs that May Induce Raynaud's
A systematic review by Khouri examined the extent drugs are capable of inducing Raynaud's phenomenon (RP).
Read Article
Muscle Weakness Predicts Disability in Scleroderma
Muscle weakness was independently associated with disability in patients with scleroderma, and as muscle weakness worsened, disability also increased, according to findings from a retrospective, nested, case control study.
Read Article
Pulmonary Hypertension Earlier and More Severe in Men with Scleroderma
Pulmonary hypertension is an uncommon complication of systemic sclerosis (SSc) and historically thought to slowly evolve in those with limited scleroderma over many years.
Read Article
Mycophenolate in Scleroderma Lung Disease
Clements et al presented the results of their Scleroderma Lung Study II wherein PSS patients with interstitial lung disease were randomized to receive either 3 grams daily of mycopheonolate or 2mg/kg/day of cyclophosphamide.
Read Article
Study Backs CellCept for ILD in Scleroderma
MONTREAL -- An immunosuppressive drug was as effective as a standard agent for interstitial lung disease (ILD) associated with scleroderma, a researcher said.
Read Article
Only 1 in 5 Seek Treatment for Raynaud's
October is Raynaud's Awareness Month according to the Raynaud's Association (http://www.raynauds.org), and a whopping 80 percent of sufferers are not aware they have the disorder and do not seek treatment.
Read Article
VEGF121-Fibrin as a Potential Therapy for Skin Ulcers in Systemic Sclerosis
The etiology of systemic sclerosis (SSc) remains unclear, but appears to involve complex pathogenic interactions between the immune system, the vasculature and fibrotic processes.
Read Article